Objective: To analyze the trend in incidence of diabetes mellitus in Wenzhou City, Zhejiang Province from 2016 to 2023, so as to provide the evidence for optimizing diabetes prevention and control strategies. Methods: Data on diabetes mellitus incidence in Wenzhou City from 2016 to 2023 were collected through the diabetes surveillance platform of the Wenzhou City Chronic Disease Monitoring Information Management System. The crude incidence of diabetes mellitus was calculated and standardized using the data from the Sixth National Population Census in 2010. The average annual percent change (AAPC) was used to analyze the trend in diabetes mellitus incidence. Results: From 2016 to 2023, a total of 331 561 new cases of diabetes mellitus were reported in Wenzhou City. The crude incidence and standardized incidence were 514.55/105 and 434.94/105, respectively, showing increasing trends (AAPC=5.801% and 3.602%, both P<0.05). The crude incidence and standardized incidence for males were 511.89/105 and 439.73/105, respectively, with increasing trends (AAPC=7.129% and 4.825%, both P<0.05); for females, the crude incidence and standardized incidence were 517.40/105 and 434.31/105, respectively, also showing increasing trends (AAPC=4.402% and 2.502%, both P<0.05). The incidence was relatively high in the age group of 70-<80 years, reaching 1 418.90/105. Except for the 50-<60 and ≥80 years age groups, the crude incidence in groups aged 0-<10 years, 10-<20 years, 20-<30 years, 30-<40 years, 40-<50 years, 60-<70 years, and 70-<80 years all showed increasing trends (AAPC=17.742%, 14.082%, 8.204%, 8.748%, 4.866%, 6.475%, and 9.853%, all P<0.05). The crude incidence of type 2 diabetes mellitus and gestational diabetes mellitus were 423.98/105 and 93.39/105, respectively, showing increasing trends (AAPC=7.858% and 15.359%, both P<0.05). The crude incidence of type 1 diabetes mellitus was 5.20/105, with no statistically significant trend (P>0.05). Conclusions The overall incidence of diabetes mellitus in Wenzhou City from 2016 to 2023 showed an increasing trend, with a relatively rapid increase among males and children and adolescents. The incidence was higher among the elderly, and the cases were predominantly type 2 diabetes.

Objective: To analyze the changing trend of female breast cancer incidence in Wenzhou City, Zhejiang Province from 2015 to 2022, so as to provide the evidence for optimizing breast cancer prevention and control strategies. Methods: Data on female breast cancer incidence in Wenzhou City from 2015 to 2022 were collected through the Wenzhou Chronic Disease Collaborative Management System. The crude incidence, truncated incidence for 35-64 years, and cumulative incidence for 0-74 years were calculated. The Chinese population age-standardized incidence and the world population age-standardized incidence were calculated using the age composition of the standard population from the Fifth National Population Census in 2000 and Segi's world standard population structure, respectively. The average annual percent change (AAPC) was used to analyze trend in female breast cancer incidence from 2015 to 2022. Results: From 2015 to 2022, the crude incidence, Chinese population age-standardized incidence, world population age-standardized incidence, truncated incidence for 35-64 years, and cumulative incidence for 0-74 years in Wenzhou City were 61.19/105, 42.73/105, 39.73/105, 104.50/105, and 4.23%, respectively, showing upward trends (AAPC=5.950%, 4.535%, 4.592%, 4.011%, and 4.897%, all P<0.05). The crude incidence (P<0.05), Chinese population age-standardized incidence, world population age-standardized incidence, truncated incidence for 35-64 years (P<0.05), and cumulative incidence for 0-74 years (P<0.05) among urban female were all higher than those in rural areas. From 2015 to 2022, the crude incidence, Chinese population age-standardized incidence, and world population age-standardized incidence among urban female showed upward trends (AAPC=2.899%, 1.837%, and 1.794%, all P<0.05), while the trends in the truncated incidence for 35-64 years, and cumulative incidence for 0-74 years were not statistically significant (both P>0.05). Among rural female, the crude incidence, Chinese population age-standardized incidence, the world population age-standardized incidence, truncated incidence for 35-64 years, and cumulative incidence for 0-74 years all showed upward trends (AAPC=6.981%, 5.457%, 5.648%, 5.172%, and 6.087%, all P<0.05). From 2015 to 2022, the crude incidence of breast cancer among female in Wenzhou City, urban areas, and rural areas first increased and then decreased with age. The crude incidence of breast cancer in Wenzhou City and rural areas peaked in the 55-<60 age group, at 136.07/105 and 128.16/105, respectively. The crude incidence of breast cancer among urban female exhibited two peaks: 142.08/105 in the 45-<50 age group and 161.95/105 in the 55-<60 age group. Conclusion From 2015 to 2022, the incidence of breast cancer among female in Wenzhou City was relatively high and showed an upward trend; the incidence was higher in urban areas, while the incidence of increase was more pronounced in rural areas, with the peak incidence occurring among female aged 55-<60 years.

In 2022， Hainan provincial government launched the project for the prevention and control of viral hepatitis with the goals of a hepatitis B screening rate of 90%， a diagnostic rate of 90%， and a treatment rate of 80% among people aged 18 years and above by the year 2025， and the main intervention measures include population-based prevention， case screening， antiviral therapy， and health management. As of December 31， 2024， a total of 6.875 million individuals in the general population had been screened for hepatitis B， with a screening rate of 95.6%. A total of 184 710 individuals with positive HBsAg were identified， among whom 156 772 were diagnosed through serological reexamination， resulting in a diagnostic rate of 84.9%. A total of 50 742 patients with chronic hepatitis B were identified， among whom 42 921 had hepatitis B-specific health records established for health management， with a file establishment rate of 84.6%. A total of 31 553 individuals received antiviral therapy， with a treatment rate of 62.2%. A total of 2.503 million individuals at a high risk of hepatitis C were screened， among whom 4 870 tested positive for HCV antibody and 3 858 underwent HCV RNA testing， resulting in a diagnostic rate of 79.2%， and 1 824 individuals with positive HCV RNA were identified， among whom 1 194 received antiviral therapy， with a treatment rate of 65.5%. In addition， 159 301 individuals with negative HBsAg and anti-HBs and an age of 20 — 40 years were inoculated with hepatitis B vaccine free of charge. Through the implementation of the project for the prevention and control of viral hepatitis， a large number of hepatitis patients have been identified， treated， and managed in the province within a short period of time， which significantly accelerates the efforts to eliminate the crisis of viral hepatitis.

Objective: To investigate the trends in mortality and life loss due to falls among the elderly in Wenzhou City, Zhejiang Province, so as to provide the basis for formulating prevention and control measures for falls among the elderly. Methods: The data on fall-related deaths among the elderly aged 60 and above in Wenzhou City were collected through the Wenzhou Chronic Disease Monitoring and Management Information System from 2015 to 2023. The crude mortality was calculated and standardized using the data from the Sixth National Population Census in 2010. The life loss were measured using potential years of life lost (PYLL), average years of life lost (AYLL), and potential years of life lost rate (PYLLR). The trends in mortality and life loss among the elderly were analyzed using the annual percent change (APC) and average annual percent change (AAPC). Results: There were 11 378 deaths due to falls among the elderly in Wenzhou City from 2015 to 2023, with a crude mortality of 82.67/100 000 and a standardized mortality of 65.32/105, which appeared no significant changing trend (AAPC=3.401%、2.995%,both P>0.05). There was a tendency towards a rise from 2019 to 2023 (APC=12.592%、11.507%, both P<0.05). The majority of falls occurred at home, with 6 312 cases accounting for 55.48%. The primary types of fall-related deaths were slips, trips, and falls on the same level, with 8 541 cases representing 75.07%. The crude mortality and standardized mortality of falls in males were 76.63/105 and 60.86/105, which were lower than that in females at 88.72/100 000 and 70.33/100 000 (both P<0.05), and the trends were consistent with the overall population. The crude mortality of falls among the elderly increased with age (P<0.05). From 2015 to 2023, the crude mortality of falls among the elderly aged 60 to <65 years showed an upward trend (AAPC=4.860%, P<0.05), while no significant trend was observed in other age groups (all P>0.05). The PYLL was 5 123 person-years, the AYLL was 0.45 years per person, and the PYLLR was 0.37‰. From 2015 to 2023, PYLL showed an upward trend (AAPC=5.477%, P<0.05). The PYLL, AYLL, and PYLLR for males were 3.08 times, 3.48 times, and 2.67 times those of females, respectively. Conclusions From 2015 to 2023, the mortality of falls among the elderly in Wenzhou City had remained relatively stable. However, PYLL showed an upward trend. Males and older seniors were key groups for falls prevention. It is recommended to enhance health education and promote age-friendly home modifications to prevent falls among the elderly.

Objective: To investigate the trends in mortality and life loss of gastric cancer in Wenzhou City, Zhejiang Province from 2014 to 2023, so as to provide the evidence for formulating the prevention and control strategy for gastric cancer. Methods: The surveillance on causes of death data of permanent residents in Wenzhou City were collected through the Wenzhou Chronic Disease Monitoring and Management Information System from 2014 to 2023. The crude mortality of gastric cancer was calculated, and standardized by the data from the Sixth Chinese National Population Census in 2010. The life loss were measured using potential years of life lost (PYLL) and rate of potential years of life lost (PYLLR). The characteristics of mortality and life loss of gastric cancer in different genders and age groups were described. The trends in mortality and PYLLR of gastric cancer were analyzed using the average annual percent change (AAPC). Results: Totally 17 080 deaths were reported due to gastric cancer in Wenzhou City from 2014 to 2023, accounting for 12.58% and ranking third in the order of malignant tumor deaths. The crude mortality of gastric cancer was 20.73/105, and the standardized mortality was 15.22/105, showing decreasing trends (AAPC=-3.311%, -6.470%, both P<0.05). The crude mortality of gastric cancer was 29.22/105 in men and 11.61/105 in women, with standardized mortality rates of 20.81/105 and 8.74/105 (both P<0.05). The crude mortality of gastric cancer appeared a tendency towards a rise with increasing age (P<0.05), reaching the highest rate of 225.88/105 in the group aged 80 to <85 years. The PYLL and PYLLR of gastric cancer were 107 607.50 person-years and 1.37‰. The PYLLR appeared a tendency towards a decline from 2014 to 2023, with AAPC of -6.667% (P<0.05). Conclusions The mortality and PYLLR of gastric cancer in Wenzhou City appeared a tendency towards a decline from 2014 to 2023. Men and the elderly populations were the key groups for the prevention and treatment of gastric cancer.

Objective: To investigate the association between overweight, obesity, central obesity and hypertension, so as to provide the basis for formulating targeted hypertension prevention and control strategies. Methods: Permanent residents aged ≥18 years were selected in Wenzhou City, Zhejiang Province from June 2023 to August 2024 by a multistage cluster random sampling method. Data on demographic information, lifestyle, height, weight, waist circumference (WC), blood pressure, and blood biochemical indicators were collected through questionnaire surveys, physical examinations, and laboratory tests. The prevalence of hypertension was calculated and standardized using the data of the Sixth National Population Census in 2010. Body mass index (BMI) was calculated to determine overweight and obesity, while WC was used to identify central obesity. The association between overweight, obesity, central obesity and hypertension were analyzed using multivariable logistic regression models. Results: A total of 38 593 residents were surveyed, including 19 481 (50.48%) males and 19 112 (49.52%) females. The median age was 46.00 (interquartile range, 26.00) years. The rates of overweight, obesity, and central obesity were 32.74% (12 634 individuals), 10.27% (3 963 individuals), and 27.87% (10 755 individuals), respectively. There were 11 813 cases of hypertension, with a prevalence and standardized prevalence of 30.61% and 24.41%, respectively. Multivariable logistic regression analysis showed that after adjusting for demographic information, lifestyle, diabetes and dyslipidemia, the likelihood of hypertension in the overweight and obesity groups was 1.927 (95%CI: 1.815-2.045) times and 3.724 (95%CI: 3.404-4.073) times that of the normal BMI group, respectively. The likelihood of hypertension in the central obesity group was 2.346 (95%CI: 2.214-2.486) times that of the normal WC group. The likelihood of hypertension in the central obesity only, overweight only, overweight with central obesity, obesity only and obesity with central obesity groups was 1.586 (95%CI: 1.391-1.809), 1.704 (95%CI: 1.582-1.835), 2.433 (95%CI: 2.254-2.626), 1.768 (95%CI: 1.424-2.194), and 4.466 (95%CI: 4.053-4.921) times that of the normal BMI and WC group, respectively. Conclusions Overweight, obesity and central obesity were all associated with hypertension among adult residents. The highest likelihood of hypertension was observed among adult residents with both general obesity and central obesity.

BACKGROUND:Neuropilin 1 plays a critical role in fracture healing,especially in osteogenesis-angiogenesis coupling. Osteogenesis-coupled angiogenesis is vital for fracture healing,including angiogenesis and bone formation (especially H-type vessel formation) and their association. OBJECTIVE:To review the research progress of neuropilin 1 in promoting osteogenesis-coupled angiogenesis during fracture healing.METHODS:The literature search was performed in the PubMed and Chinese National Knowledge Infrastructure databases for articles published from January 1982 to April 2024 using the search terms "Neuropilin-1,neuropilin 1,NRP1,neuropilin-1,NRP-1,Neuropilin 1,Nrp1,Nrp-1." We identified 43 articles associated with fracture healing,H-type vessels,arteries,bone cells,and angiogenesis-osteogenesis coupling. Moreover,24 articles were searched manually. Finally,67 papers were included.RESULTS AND CONCLUSION:(1) Angiogenesis,osteoblastogenesis,and their association were critical for angiogenesis-osteogenesis coupling during fracture healing. Especially H-type vessel formation was critical during fracture healing. H-type vessels consisted of endothelial cells and pericytes. Osteoblasts,osteoclasts,chondrocytes,and other skeletal cells were critical contributors to new bone formation. (2) Neuropilin 1 enhanced endothelial cell migration and stabilization,increased stability of endothelial cells and pericytes,and strengthened the link of endothelial cells and pericytes to initiate angiogenesis by vascular endothelial growth factor and platelet-derived growth factor. (3) Neuropilin 1 promoted bone regeneration by suppressing osteoclastogenesis and enhancing osteoclasts and chondrocyte formation. (4) Neuropilin 1 was a key factor in angiogenesis-osteogenesis coupling. (5) Topical application of neuropilin 1 and relative biologics,and combination neuropilin 1,nano drug-loading systems,and polymerized smart materials provided a new idea for treatment of fractures and hold great promise for extensive applications.

BACKGROUND:Neuropilin 1 plays a critical role in fracture healing,especially in osteogenesis-angiogenesis coupling. Osteogenesis-coupled angiogenesis is vital for fracture healing,including angiogenesis and bone formation (especially H-type vessel formation) and their association. OBJECTIVE:To review the research progress of neuropilin 1 in promoting osteogenesis-coupled angiogenesis during fracture healing.METHODS:The literature search was performed in the PubMed and Chinese National Knowledge Infrastructure databases for articles published from January 1982 to April 2024 using the search terms "Neuropilin-1,neuropilin 1,NRP1,neuropilin-1,NRP-1,Neuropilin 1,Nrp1,Nrp-1." We identified 43 articles associated with fracture healing,H-type vessels,arteries,bone cells,and angiogenesis-osteogenesis coupling. Moreover,24 articles were searched manually. Finally,67 papers were included.RESULTS AND CONCLUSION:(1) Angiogenesis,osteoblastogenesis,and their association were critical for angiogenesis-osteogenesis coupling during fracture healing. Especially H-type vessel formation was critical during fracture healing. H-type vessels consisted of endothelial cells and pericytes. Osteoblasts,osteoclasts,chondrocytes,and other skeletal cells were critical contributors to new bone formation. (2) Neuropilin 1 enhanced endothelial cell migration and stabilization,increased stability of endothelial cells and pericytes,and strengthened the link of endothelial cells and pericytes to initiate angiogenesis by vascular endothelial growth factor and platelet-derived growth factor. (3) Neuropilin 1 promoted bone regeneration by suppressing osteoclastogenesis and enhancing osteoclasts and chondrocyte formation. (4) Neuropilin 1 was a key factor in angiogenesis-osteogenesis coupling. (5) Topical application of neuropilin 1 and relative biologics,and combination neuropilin 1,nano drug-loading systems,and polymerized smart materials provided a new idea for treatment of fractures and hold great promise for extensive applications.

Objective: To investigate the mortality and life loss of female breast cancer in Wenzhou City, Zhejiang Province from 2014 to 2022, so as to provide the evidence for prevention and control of breast cancer. Methods: Data of female breast cancer deaths in Wenzhou City were collected through the Wenzhou Chronic Disease Monitoring and Management information System from 2014 to 2012. The mortality of breast cancer was calculated, and standardized by the data from the Sixth Chinese National Population Census in 2010 (Chinese-standardized rate) and the world standard population first introduced by Segi (world-standardized rate). The life loss were measured using potential years of life lost (PYLL), rate of potential years of life lost (PYLLR) and average years of life lost (AYLL). The trends in mortality, PYLLR and AYLL were analyzed using the average annual percent change (AAPC). Results: Totally 2 523 deaths were reported due to breast cancer from 2014 to 2022, ranking fifth in the order of female malignant tumor deaths. The crude mortality of female breast cancer was 7.13/105, showing an increasing trend with AAPC of 2.186% (P<0.05). The Chinese population-standardized mortality and global population-standardized mortality were 5.93/105 and 4.39/105, showing no significant trend with AAPC of -0.617% and -0.602% (both P>0.05), respectively. The crude mortality of female breast cancer appeared a tendency towards a rise with age (P<0.05). The crude mortality of breast cancer in females aged 65 years and older showed an increasing trend (AAPC=3.283%, P<0.05), but there were no significant tendency aged 15 to <45 years and 45 to <65 years (AAPC=-1.011% and -1.850%, both P>0.05). The PYLL, PYLLR and AYLL of breast cancer were 41 227.50 person-years, 1.23‰ and 19.44 years per person, respectively. AYLL showed a decreasing trend (AAPC=-1.969%, P<0.05), and PYLLR showed no significant trend (AAPC=-0.527%, P>0.05). Conclusions The mortality of female breast cancer in Wenzhou City appeared a tendency towards a rise from 2014 to 2022, and AYLL appeared a downward trend. Females aged 65 years and older were the key groups for the prevention and control of breast cancer.

Objective:To investigate the effect of serine/arginine-rich splicing factor 2 (SRSF2) on ferroptosis and its possible mechanism in glioblastoma cells.Methods:The online database of gene expression profiling interactive analysis 2 (GEPIA 2) and Chinese Glioma Genome Atlas were used to analyze the expression of SRSF2 in glioblastoma tissue and its association with patients prognosis. To validate the findings of the online databases, the pathological sections of glioblastoma and non-tumor brain tissues from Tianjin Medical University General Hospital, Tianjin, China were collected and analyzed by using immunohistochemistry. Silencing SRSF2 gene expression in glioblastoma cells by siRNA was analyzed with Western blot. The proliferation index was detected by using CCK8 assay. The rescued experiment was conducted by using expression plasmid of pcDNA3.1(+)-SRSF2. The activity of ferroptosis was assessed by using the levels of iron ions and malondialdehyde in glioblastoma cells and the changes in the ratio of glutathione to oxidized glutathione. The changes of gene expression and differential pre-mRNA alternative splicing (PMAS) induced by SRSF2 were monitored by using the third-generation sequencing technology analysis, namely Oxford nanopore technologies (ONT) sequencing analysis.Results:SRSF2 expression was higher in glioblastoma tissues than non-tumor brain tissues. Immunohistochemistry also showed a positive rate of 88.48%±4.60% in glioblastoma tissue which was much higher than the 9.97%±4.57% in non-tumor brain tissue. The expression of SRSF2 was inversely correlated with overall and disease-free disease survivals ( P<0.01). The proliferation index of glioblastoma cells was significantly reduced by silencing with SRSF2 siRNA ( P<0.01) and could be reversed with transfection of exogenous SRSF2. The levels of intracellulariron ions and malondialdehyde increased ( P<0.05), but the glutathione/oxidized glutathione ratio and the expression of key proteins in the glutathione pathway remained unchanged ( P>0.05). ONT sequencing results showed that silencing SRSF2 in glioblastoma cells could induce a significant alternative 3' splice site change on ferroptosis suppressor protein 1 (FSP1). Conclusion:SRSF2 inhibits the ferroptosis in glioblastoma cells and promotes their proliferation, which may be achieved by regulating FSP1 PMAS.